11-substituted (R)-aporphines: Synthesis, pharmacology, and modeling of D-2A and 5-HT1A receptor interactions

被引:34
作者
Hedberg, MH
Linnanen, T
Jansen, JM
Nordvall, G
Hjorth, S
Unelius, L
Johansson, AM
机构
[1] UNIV UPPSALA,CTR BIOMED,DEPT ORGAN PHARMACEUT CHEM,S-75123 UPPSALA,SWEDEN
[2] ASTRA RES CTR AB,PRECLIN RES & DEV,S-15185 SODERTALJE,SWEDEN
[3] UNIV GOTHENBURG,DEPT PHARMACOL,S-41390 GOTHENBURG,SWEDEN
关键词
D O I
10.1021/jm960189i
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of C11-substituted (R)-aporphines and C11-oxygenated (R)-noraporphines has been synthesized and evaluated for central serotonergic and dopaminergic effects in vitro and in vivo. The various C11-substituents were introduced using efficient nickel- and palladium-catalyzed reactions of the corresponding triflate (R)-11-[[(trifluoromethyl)sulfonyl]oxy] aporphine (6), Several compounds display high affinity to serotonin 5-HT1A receptors in spite of major differences in steric bulk and electronic properties of the various C11-substituents. A change of the N-methyl group of the nonselective 3 to H [23, (R)-11-hydroxynoraporphine] or propyl [2, (R)-11-hydroxy-N-propylnoraporphine] increases the selectivity for 5-HT1A receptors (100-fold) and dopamine D-2A receptors (3-fold), respectively. Compounds 3 and 23 have similar affinities to 5-HT1A receptors, whereas the propyl substituent of 2 not only enhances the selectivity for D-2A receptors but also increases the D-2A affinity. Modeling of ligand-receptor binding site interactions yielded an interaction site model for the 5-HT1A receptor that describes a gradual change in binding mode for C11-hydroxy, -methoxy-, and -phenyl-substituted derivatives. Hydrogen bonding is hereby gradually replaced by van der Waals interactions involving a relatively large lipophilic pocket. The derived D-2A receptor model can accommodate both the N-propyl substituent of 2 and the C11-ethyl substituent of 11 [(R)-11-ethylaporphine].
引用
收藏
页码:3503 / 3513
页数:11
相关论文
共 63 条
[1]  
AGHAJANIAN GK, 1978, ESSAYS NEUROCHEMISTR, P2
[2]  
Allinger N. L., 1980, QCPE, P395
[3]   ADRENERGIC MECHANISMS [J].
ANDEN, NE ;
CARLSSON, A ;
HAGGENDAL, J .
ANNUAL REVIEW OF PHARMACOLOGY, 1969, 9 :119-+
[4]   8-HYDROXY-2-(DI-NORMAL-PROPYLAMINO)TETRALIN, A NEW CENTRALLY ACTING 5-HYDROXYTRYPTAMINE RECEPTOR AGONIST [J].
ARVIDSSON, LE ;
HACKSELL, U ;
NILSSON, JLG ;
HJORTH, S ;
CARLSSON, A ;
LINDBERG, P ;
SANCHEZ, D ;
WIKSTROM, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1981, 24 (08) :921-923
[5]   RECEPTOR AFFINITIES OF APORPHINE ENANTIOMERS IN RAT-BRAIN TISSUE [J].
BALDESSARINI, RJ ;
KULA, NS ;
ZONG, RS ;
NEUMEYER, JL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 254 (1-2) :199-203
[6]  
BURKERT U, 1982, MOL MECHANICS
[7]   PALLADIUM-CATALYZED TRIETHYLAMMONIUM FORMATE REDUCTION OF ARYL TRIFLATES - A SELECTIVE METHOD FOR THE DEOXYGENATION OF PHENOLS [J].
CACCHI, S ;
CIATTINI, PG ;
MORERA, E ;
ORTAR, G .
TETRAHEDRON LETTERS, 1986, 27 (45) :5541-5544
[8]   ENANTIOMERS OF 11-HYDROXY-10-METHYLAPORPHINE HAVING OPPOSING PHARMACOLOGICAL EFFECTS AT 5-HT1A RECEPTORS [J].
CANNON, JG ;
MOE, ST ;
LONG, JP .
CHIRALITY, 1991, 3 (01) :19-23
[9]   A-RING ORTHO-DISUBSTITUTED APORPHINE DERIVATIVES AS POTENTIAL AGONISTS OR ANTAGONISTS AT SEROTONERGIC 5-HT1A RECEPTORS [J].
CANNON, JG ;
FLAHERTY, PT ;
OZKUTLU, U ;
LONG, JP .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (11) :1841-1845
[10]   PREPARATION AND PHARMACOLOGICAL EVALUATION OF ENANTIOMERS OF CERTAIN NONOXYGENATED APORPHINES - (+)- AND (-)-APORPHINE AND (+)- AND (-)-10-METHYLAPORPHINE [J].
CANNON, JG ;
RAGHUPATHI, R ;
MOE, ST ;
JOHNSON, AK ;
LONG, JP .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (10) :1316-1318